Navigation Links
The Foundation for Biomedical Research Announces Winners of the 7th Annual Michael E. DeBakey Journalism Awards
Date:6/19/2008

is the nation's oldest and largest organization devoted to educating the public about the essential role of humane animal research in the quest for medical advancements, treatments, and cures for both humans and animals. For more information visit http://www.fbresearch.org.


'/>"/>
SOURCE Foundation for Biomedical Research
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Canopus BioPharma Strengthens its CB1400 Platform Technology for Mucositis and Oncology Treatments Through License Agreement With Wisconsin Alumni Research Foundation
2. Quantum Immunologics, Inc. and the South Alabama Medical Science Foundation Announce an Early Clinical Evaluation of a Novel Immuno-therapeutic Vaccine for Treating Advanced Human Breast Carcinomas
3. Statement From the Lupus Foundation of America Regarding the Release of Top-Line Results From a Study of Rituxan for the Treatment of Lupus
4. The COSHAR Foundation Launches National Childhood Immunization Awareness Campaign During National Infant Immunization Week (April 19-26)
5. Michael J. Fox Foundation Announces $5.6-Million Award for Phase 2 Clinical Trial Studying Neuroprotective Potential of Inosine
6. Data From Ortho Biotech-Sponsored Studies to be Presented at National Kidney Foundation 2008 Spring Clinical Meetings
7. Michael J. Fox Foundation Commits up to $10 Million for Pre-Clinical Drug Development Under Therapeutics Development Initiative
8. Cystic Fibrosis Foundation Announces Positive Early Results for Phase 2 Clinical Trial of VX-770 - an Oral Compound to Treat CF
9. New Michael J. Fox Foundation Initiative Will Drive Development of Web-Based Tools to Increase Patient Participation in Parkinsons Clinical Trials
10. Gates Foundation Seeks Proposals for Innovative Global Health Research
11. Pharmatech Teams up With Systems Medicine LLC and the Sarcoma Foundation of America for a Phase II Myxoid Liposarcoma Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)... Imaging, LLC, an independent provider of CT, MRI ... and healthcare providers, is excited to announce it ... Health Care, a nationally-recognized, prestigious gold seal of ... Shared Imaging accreditation is system-wide for its mobile ...
(Date:12/4/2009)... Ill., Dec. 4 Hospira, Inc. (NYSE: ... delivery company, today announced the launch of its next-generation ... (I.V.) medications and solutions, and now offers a complete ... award-winning, environmentally responsible VisIV product. The launch of the ...
(Date:12/4/2009)... Suneva Medical, a privately-held aesthetic medical device company, today ... and Chief Financial Officer. In this role, Mr. ... functions including finance, accounting, IT, IR, administration and human ... senior management team. ,, "One of my key ...
Breaking Medicine Technology:Shared Imaging Earns The Joint Commission's Accreditation for Ambulatory Health Care 2Hospira Expands VisIV(TM) Portfolio to Offer Complete Range of Environmentally Friendly I.V. Containers 2Hospira Expands VisIV(TM) Portfolio to Offer Complete Range of Environmentally Friendly I.V. Containers 3Hospira Expands VisIV(TM) Portfolio to Offer Complete Range of Environmentally Friendly I.V. Containers 4Suneva Medical Announces Corporate Developments Including Appointment of Philip Ranker as Chief Financial Officer 2Suneva Medical Announces Corporate Developments Including Appointment of Philip Ranker as Chief Financial Officer 3Suneva Medical Announces Corporate Developments Including Appointment of Philip Ranker as Chief Financial Officer 4Toms of Maine Invites Public Participation in 50 States for Good Program 48207 1Toms of Maine Invites Public Participation in 50 States for Good Program 48207 2More Ontario children are getting diagnosed with diabetes 3A ICES study 48205 1Common chemotherapy drug triggers fatal allergic reactions 8748 1Common chemotherapy drug triggers fatal allergic reactions 8748 2Common chemotherapy drug triggers fatal allergic reactions 8748 3
... June 11, 2007 (MARKET WIRE via COMTEX ... (<a target=,"_blank" href="http://www.myriad.com/">www.myriad.com ),announced today that it ... and a "Randomized Withdrawal" clinical trial,design with ... at the Alzheimer's Association Prevention Conference held,June ...
... /PRNewswire-FirstCall/ - Paul S.,Aisen, M.D., Professor of ... and principal investigator in the United,States of ... trial,for tramiprosate (ALZHEMED(TM)) will present today an ... treatment of,Alzheimer's disease (AD). The presentation by ...
Other Medicine Technology:Myriad Genetics Presents Mathematical Comparison of Disease,Modification Trial Designs at Alzheimer's ConferenceCurrent,Flurizan Phase 3 Study Design May Demonstrate Disease Modification 2Myriad Genetics Presents Mathematical Comparison of Disease,Modification Trial Designs at Alzheimer's ConferenceCurrent,Flurizan Phase 3 Study Design May Demonstrate Disease Modification 3Myriad Genetics Presents Mathematical Comparison of Disease,Modification Trial Designs at Alzheimer's ConferenceCurrent,Flurizan Phase 3 Study Design May Demonstrate Disease Modification 4Myriad Genetics Presents Mathematical Comparison of Disease,Modification Trial Designs at Alzheimer's ConferenceCurrent,Flurizan Phase 3 Study Design May Demonstrate Disease Modification 5At the 2007 Alzheimer's Association International Conference on the,Prevention of Dementia - Neurochem's U.S. Principal Investigator,Presents Update on Tramiprosate (Alzhemed) 2At the 2007 Alzheimer's Association International Conference on the,Prevention of Dementia - Neurochem's U.S. Principal Investigator,Presents Update on Tramiprosate (Alzhemed) 3At the 2007 Alzheimer's Association International Conference on the,Prevention of Dementia - Neurochem's U.S. Principal Investigator,Presents Update on Tramiprosate (Alzhemed) 4
(Date:12/7/2009)... NEW ORLEANS, Dec. 7 Cell Therapeutics, ... that Ruth Pettengell, M.D. of St. George,s Hospital, ... 2009 American Society of Hematology ("ASH") Annual Meeting ... (PIX 301) clinical trial of pixantrone (the "PIX ... non-Hodgkin,s lymphoma ("NHL") patients who have failed ...
(Date:12/6/2009)... OAK BROOK, Ill., Dec. 7 The ... center (AMC) members for their achievements in UHC,s ... 10 organizations are noted for modeling best practices ... (Photo: http://www.newscom.com/cgi-bin/prnh/20091207/CG21708 ) ,, The winners were ... calculation that includes contract portfolio participation and use ...
(Date:12/6/2009)... discovered that the loss of a key segment of DNA ... study to show that this kind of genetic alteration can ... . , The study, led by Dr Sadaf Farooqi from ... Wellcome Trust Sanger Institute, looked at 300 children with severe ... for types of mutation known as copy number variants (CNVs). ...
(Date:12/6/2009)... ORLEANS, Dec. 6 Onyx Pharmaceuticals, Inc. ... data from the pivotal Phase 2b 003-A1 study, ... is well-tolerated in heavily pre-treated relapsed and refractory ... at the ASH/ASCO Joint Symposium at the 51st ... (ASH) in New Orleans. Enrollment in this trial ...
(Date:12/6/2009)... www.sleeping-with-a-sleeping-disorder.com is asking people ,who have ... aids from around the world to donate their ... submissions will be compiled in an ebook titled ... be sold from the website in early January ... proceeds ,from sales of the E-book to three ...
Breaking Medicine News(10 mins):Health News:Pixantrone Produces 250% Relative Improvement in 1 Year Progression Free Survival for Patients With Relapsed/Refractory, Aggressive Non-Hodgkin's Lymphoma Across All Measured Risk Factors - Updated Follow-Up Data 2Health News:Pixantrone Produces 250% Relative Improvement in 1 Year Progression Free Survival for Patients With Relapsed/Refractory, Aggressive Non-Hodgkin's Lymphoma Across All Measured Risk Factors - Updated Follow-Up Data 3Health News:Pixantrone Produces 250% Relative Improvement in 1 Year Progression Free Survival for Patients With Relapsed/Refractory, Aggressive Non-Hodgkin's Lymphoma Across All Measured Risk Factors - Updated Follow-Up Data 4Health News:Pixantrone Produces 250% Relative Improvement in 1 Year Progression Free Survival for Patients With Relapsed/Refractory, Aggressive Non-Hodgkin's Lymphoma Across All Measured Risk Factors - Updated Follow-Up Data 5Health News:Recognized Top Performers in UHC Supply Chain 2Health News:Genetic studies reveal new causes of severe obesity in childhood 2Health News:Carfilzomib Safety Data From Ongoing Phase 2b Pivotal Trial in Relapsed and Refractory Multiple Myeloma Show Promising Safety and Tolerability 2Health News:Carfilzomib Safety Data From Ongoing Phase 2b Pivotal Trial in Relapsed and Refractory Multiple Myeloma Show Promising Safety and Tolerability 3Health News:Carfilzomib Safety Data From Ongoing Phase 2b Pivotal Trial in Relapsed and Refractory Multiple Myeloma Show Promising Safety and Tolerability 4Health News:Carfilzomib Safety Data From Ongoing Phase 2b Pivotal Trial in Relapsed and Refractory Multiple Myeloma Show Promising Safety and Tolerability 5Health News:Donate a Herbal Natural Sleep Aid to the Internet's First "Natural Sleep Aids E-book" Written by People Just Like You 2
... SHENZHEN, China, Feb. 14 /Xinhua-PRNewswire-FirstCall/ -- China Display,Technologies, ... "the,Company"), a leading manufacturer of optoelectronic products, specializing,in ... for LCD displays in,China, today announced its Vice ... Officer, Mr. Kam Ming Yip will present at ...
... of genes that prevent cell death in those with ... Researchers from Saint Louis University report that a pile-up ... finding which could point to new therapies for the ... finding new treatments for lupus," said Dr. Jill Buyon, ...
... nomination campaign, some candidates health care plans have been ... has been used to attack health reform proposals in ... Opinion Research Program at the Harvard School of Public ... split on whether a socialized medical system would be ...
... 14 Workplace stress is the,most frequently cited ... acknowledge that stress is affecting business performance,few are ... surveys by Watson,Wyatt Worldwide, a leading global consulting ... percent) say stress caused by working,long hours is ...
... Officials at,Southern Research Institute today announced that Wilson ... has been named Vice,President of its Drug Discovery ... "We are very pleased that Dr. Knight has ... research program," said John A. "Jack" Secrist,III, Ph.D., ...
... WASHINGTON, Feb. 14 Lung Cancer Alliance,announced today ... joined its Board of Directors., LCA Board ... the,following statement:, "Secretary Mineta,s remarkable career in ... leadership on national security, transportation,infrastructure and technology issues ...
Other Medicine News:Health News:China Display Technologies, Inc. to Present at Roth Conference 2Health News:China Display Technologies, Inc. to Present at Roth Conference 3Health News:Overabundance of Immune Cells Might Trigger Lupus 2Health News:Overabundance of Immune Cells Might Trigger Lupus 3Health News:Poll finds Americans split by political party over views on socialized medicine 2Health News:Poll finds Americans split by political party over views on socialized medicine 3Health News:Few Employers Addressing Workplace Stress, Watson Wyatt Surveys Find 2Health News:Few Employers Addressing Workplace Stress, Watson Wyatt Surveys Find 3Health News:Southern Research Institute Names Blaine Knight Vice President of Drug Discovery 2Health News:Secretary Norman Y. Mineta Joins Lung Cancer Alliance Board of Directors 2
... The Acclaim 7000 Nd:YAG laser ... by offering cosmetic procedures such as ... facial veins, our Dermique LaserFACIAL for ... offers selectable parameters for customizing treatment ...
... laser beam is delivered through an ultra thin ... the operator full freedom of movement when performing ... with a wide range of handpieces. Handpieces ... mm and 16 mm. Straight and angled ...
VERSASTEP™ Reposable Reusable Components (Standard Length)....
VERSASTEP™ Reposable Single Use Trocar For use with VERSASTEP™ Reusable Cannula, Dilator....
Medicine Products: